In a landmark judgment likely to benefit Indian generic drug manufacturers in a big way, the US Supreme Court has ruled against patenting of products with slight modifications.
The contract research and manufacturing services may soon replace generic drugs manufacturing as the preferred business option for Indian pharmaceutical industry, if growing revenues from CRAMS business is any indication.
Ranbaxy Laboratories, the country's biggest drugmaker, is all set to focus its energies in developing and marketing niche products where price erosion is minimal
The quantum of hike had not yet been worked out, but it was likely to be Rs 2 a litre for petrol and Re 1 a litre for diesel.
The pace of privatisation of the Indian healthcare segment is expected to be the fastest in the coming years.
The proposal to hive off the LNG terminal at the revived Dabhol power plant in Maharashtra is likely to be scrapped, with promoters and financiers agreeing to pump in Rs 24 billion to restart construction work at the plant.
The shares of oil marketing companies have been firming up in the current financial year though the Indian crude oil basket is quoting above $65 a barrel, as investors took long-term.
In all, Reliance has a stake in 34 exploration blocks in the country.
Over 30 domestic pharmaceutical companies, including Ranbaxy, Cipla, Nicholas Piramal, Zydus Cadila and Torrent, face a possible ban on the sale of the generic version of Merck's pain management drug in the Indian market.
With the price of gas from its fields in the Krishna-Godavari basin expected to be higher than rivals, Reliance Industries is targeting automobiles and domestic users because power and fertiliser plants may not be able to afford it.
The Ministry Of Petroleum and Natural Gas has ruled out a hike in the prices of petrol and diesel in the near future even as the price of the Indian basket of crude oil continues to remain above $65 a barrel.
Even as Minister of State for Petroleum Dinsha Patel has told the Rajya Sabha that new connections are easily available for genuine customers, householders all over India are facing an acute shortage of LPG cylinders.
Data from the Central Information Commission, the apex body that hears complaints regarding denial of information under RTI, shows that corporate houses are increasingly using RTI to extract information from public authorities.
Pfizer's blockbuster drug Viagra (sildenafil citrate), hitherto approved for use in treatment of erectile dysfunction, may soon acquire a new identity as a "life saving drug" in treating pulmonary arterial hypertension in children.
The venue of the battle by Swiss multinational Novartis AG against the rejection of its patent application for blockbuster cancer drug Gleevac will now shift to the Patent Appellate Board's office.
India may be trying to become a crude oil refining hub but the country's apex planning body has raised doubts on the feasibility of adding more refining capacity.
There seem to be some more delays in the pipeline for the decade-old Bathinda refinery project of Hindustan Petroleum Corporation in which Mittal Investments recently announced its decision to pick up 49 per cent stake.
The competition between the two main players vying to lay cross-country natural gas pipelines has undergone a volte-face.
Australia has joined the UK, USA and Canada in warning its citizens against using unapproved traditional medicines from India and China.
Hetero is the only Indian partner of multinational drug major Roche Scientific for the manufacture and supply of the latter's patented drug, Tamilflu in developing countries.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances